Drugs / rDEN3Δ30/31-7164
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05691530 | Mar 2023 → Apr 2025 | dengue disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN3Δ30/31-7164 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05691530 ↗ |
| Modality | Vaccine | “The rDEN3Δ30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3' untranslated region (UTR) of the DENV-3 Sleman/78 strain.” NCT05691530 ↗ |
| Route | Subcutaneous | “The vaccine dose consists of 0.5 mL of 10\^3.3 PFU/mL of rDEN3Δ30/31-7164 plus Plasma-Lyte A pH 7.4 diluent delivered subcutaneously into the deltoid area on day 0.” NCT05691530 ↗ |